ArticleCurrent treatment options in psychiatry2020
Cannabis and the Developing Adolescent Brain.
Article in Current treatment options in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 52 citations in OpenAlex.
- Cannabis legalization and early adolescent expectancies: Findings from the adolescent brain cognitive development study.Drug and alcohol dependence · 2026Article
- Household cannabis cessation and adolescent mental health outcomes in a prospective cohort study.BMC medicine · 2026Article
- Trends in hospitalizations for cannabinoid hyperemesis syndrome in Canada, 2016-17 to 2024-25.Frontiers in public health · 2026Article
- Associations Between State Cannabis and Alcohol Policy Restrictiveness and College Students' Cannabis Use, Binge Drinking and Co-Use.Substance use & misuse · 2026Article
- Exercise-induced anandamide-CB1R signaling and prefrontal-amygdala stress circuits in adolescent depression: a critical hypothesis-driven narrative review.Frontiers in psychiatry · 2026Review
- US drug policy does not align with experts' rankings of drug harms: a multi-criteria decision analysis.Harm reduction journal · 2025Article
- Adult-use cannabis legalization in the united states: a scoping review of outcome monitoring recommendations.BMC public health · 2025Article
- Trends in U.S. Adolescent Use of Vaping and Flavored Solutions for Marijuana Consumption, 2021-2024.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2025Article
- Oral microbial profiles in young adults with cannabis use disorder.Drug and alcohol dependence · 2025Article
- Review of Cannabis-Related Programmatic Activities for Drug-Free Communities (DFC) Support Program Coalitions.Journal of community health · 2025Article
- Central Executive Network drives delta-9-tetrahydrocannabinol (THC)-induced nonlinear changes in large-scale functional connectivity in adolescent nonhuman primates.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Under the Influence: Cognitive Effects of Medical Marijuana on Developing Minds.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Clinician perspectives on barriers and facilitators to the treatment of adolescent cannabis use: A qualitative study.Journal of substance use and addiction treatment · 2025Article
- Young Adult Cannabis Use and Circulating Endocannabinoid Concentrations on Cognitive Performance.Frontiers in adolescent medicine · 2025Article
- Porphyric encephalopathy in a 15-year-old girl: A case report.SAGE open medical case reports · 2025Article
- Prevalence of Blunt and Hemp Wrap Use Among Young Adults in the United States, 2022.Substance use & misuse · 2025Article
- Neurocognitive outcomes in adolescents with and without four weeks of cannabis abstinence: a randomized clinical trial using contingency management.Frontiers in psychiatry · 2025Article
- Inclusion of Individuals With Lived Experiences in the Development of a Digital Intervention for Co-Occurring Depression and Cannabis Use: Mixed Methods Investigation.JMIR formative research · 2024Article
- A test of competing mediators linking trouble sleeping to cannabis use in adolescents and emerging adults.Experimental and clinical psychopharmacology · 2024Article
- Legalization of marijuana or not? Opinions from over 38,000 residents in Taiwan.BMC public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThis review summarizes (1) recent trends in delta-9-tetrahydrocannabionol [THC] and cannabidiol (CBD) content in cannabis products, (2) neurobiological correlates of cannabis use on the developing adolescent brain, (3) effects of cannabis on psychiatric symptoms and daily functioning in youth (i.e., academic performance, cognition, sleep and driving), (4) cannabis products used to relieve or treat medical issues in youth, and (5) available treatments for cannabis use disorder in adolescence. RECENT
findingsDespite marked increases in THC content and availability of cannabis, there has been a decline in perceived risk and an increase in use of THC extract products among youth in the United States. The primary psychiatric symptoms associated with cannabis use in youth are increased risk for addiction, depressive, and psychotic symptoms. Cannabis alters endocannabinoid system function which plays a central role in modulating the neurodevelopment of reward and stress systems. To date, few studies have examined neurobiological mechanisms underlying the psychiatric sequalae of cannabis exposure in youth. Adolescent cannabis exposure results in impaired cognition, sleep, and driving ability. There are very limited FDA-approved cannabinoid medications, none of them supporting their use for the treatment of psychiatric symptoms. Behavioral therapies are currently the mainstay of treating cannabis misuse, with no pharmacotherapies currently approved by the FDA for cannabis use disorder in youth. SUMMARY: Here, we summarize the most up-to-date knowledge on the neurobiological psychiatric, and daily function effects of the most commonly used cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). We then review FDA approved medical use of cannabinoid treatments as well as pharmacological and psychological treatments for cannabis use disorder in youth. Our current understanding of the effects of cannabis on the developing brain and treatments for cannabis misuse in youth remain limited. Future research aimed at examining the neurobiological effects of cannabis, with objective measures of exposure, over the course of pediatric development and in relation to psychiatric symptoms are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.